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AdipokineObesity, characterized by excessive adiposity, is a risk factor for many metabolic pathologies, such as type 2
diabetes mellitus (T2DM). Numerous studies have shown that adipose tissue distribution may be a greater
predictor of metabolic health. Upper-body fat (visceral and subcutaneous abdominal) is commonly associated
with the unfavorable complications of obesity, while lower-body fat (gluteal–femoral) may be protective.
Current research investigations are focused on analyzing the metabolic properties of adipose tissue, in order
to better understand the mechanisms that regulate fat distribution in both men and women. This review
will highlight the adipose tissue depot- and sex-dependent differences in white adipose tissue function,
including adipogenesis, adipose tissue developmental patterning, the storage and release of fatty acids, and
secretory function. This article is part of a Special Issue entitled: Modulation of Adipose Tissue in Health and
Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Adipocytes are highly specialized cells that form and store fat in ad-
ipose tissue and play a major role in energy homeostasis in vertebrate
organisms. Obesity results from an energy surplus and is characterized
by an increased storage of lipid and expansion of adipose tissue. Obesity
modiﬁes the endocrine andmetabolic functions of adipose tissue and is
a risk factor formanyothermetabolic diseases, including type 2 diabetes
(T2DM), cardiovascular disease (CVD), atherosclerosis, and hyperten-
sion. No longer recognized as just a lipid-storage depot, white adipose
tissue (WAT) has additional properties, including insulin sensitivity
and secretory function, that contribute to the pathogenesis of obesity
and T2DM (reviewed in [1]). Hence, it is well-established that WAT
can signiﬁcantly impact metabolic health, as its development and func-
tion greatly inﬂuence whole-body metabolism.
Though overall excessive adiposity is associated with serious
co-morbidities, the distribution of body fat has been shown to be a
stronger predictor of health risk [2–8]. Numerous studies have
described differential correlations of WAT depots and metabolic risk
in humans, presumably due to intrinsic differences in function of
the adipose tissue [9–13]. The two types of WAT, visceral (VAT) and
subcutaneous (SAT), are deﬁned by location, and the mechanisms
and developmental signals that account for each depot's unique char-
acteristics are steadily emerging. In human subjects, VAT is usuallyion of Adipose Tissue in Health
rch Center, 6400 Perkins Road,
763 3030.
Tchoukalova).
rights reserved.represented by the omental depot (although it also includes the
mesenteric fat) and by the perigonadal depot (parametrial and epi-
didymal fat pad) in rodents; while SAT is represented by the abdom-
inal, gluteal and femoral depots in humans and by the inguinal fat pad
in rodents. Studies have revealed that central/abdominal (subcutane-
ous upper body and visceral) fat deposition correlates with an in-
creased susceptibility for metabolic complications [14–18], while
gluteal–femoral (lower body) adipose tissue is associated with re-
duced metabolic risk and may be protective against the adverse
health effects of obesity in both sexes [16,19–23](reviewed in [24]).
Current investigations are focused on elucidating the mechanisms,
adipose tissue-secreted factors, and developmental signals that ac-
count for regional differences in WAT development and function. It
is important to note that the developmental origin of white and
brown adipose tissue is distinct (reviewed in [25,26]), and the phys-
iological role of brown fat in human body weight regulation and
obesity-associated metabolic complications is controversial and has
not been elucidated (reviewed in [27]). This review will provide an
overview of the depot- and sex-dependent differences in important
functions of white adipose tissue, such as adipogenesis, expression
of developmental patterning transcription factors, the storage and
release of fatty acids, and secretory function.
2. Sex differences in fat distribution
Sex differences in adipose tissue distribution are well-supported
by many literature ﬁndings and are associated with whole body met-
abolic health. Women generally have higher adiposity relative to men
throughout the entire lifespan [28,29]. However, men often have
more adipose tissue distributed in the central or abdominal region
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metabolic disorders [30] (reviewed in [31] and [32]). In contrast,
women are characterized by less VAT and more SAT [30,33–35], espe-
cially in the lower body (‘gynoid’ or ‘pear’ phenotype) [36,37]. Likewise,
though women can also possess the upper-body obese phenotype, the
reduced metabolic disease risk in women has been attributed to the
propensity to store body fat in the SAT depot, particularly in the glute-
al–femoral region. Though the factors and mechanisms that govern
this sexual dimorphism are not elucidated, these characteristic android
and gynoid fat distribution patterns in men and women appear as
early as puberty (reviewed in [38]). Therefore, evidence suggests that
this distribution may be predominantly sex hormone-dependent [39]
(reviewed in [40]).
Sex steroids are endogenous modulators of adipose tissue devel-
opment and function, and may also inﬂuence, in part, the distribution
of SAT versus VAT depots (reviewed in [41]), although little is known
about the cellular and molecular mechanisms of this regulation. In
menopausal women, who have a decline in circulating estrogen levels
[42–46], visceral adiposity increases, resulting from a shift towards a
central/android body fat distribution. Postmenopausal women were
shown to have a much greater increase in VAT volume as compared to
premenopausal women [47,48]. Furthermore, women who received
hormone replacement therapy (HRT) had lower waist circumferences
and VAT than those who did not receive therapy [49–51]. Collectively,
these studies suggest that estrogen may modulate WAT distribution
by effectively reducing central adiposity in humans. Likewise, the depo-
sition of fat in the gluteal–femoral SAT depots in women versus deposi-
tion in the VAT in menmay be related to the higher level of estrogen in
premenopausal women compared to men (reviewed in [52]).
Androgens may also have depot- and gender-speciﬁc effects on
adipose tissue distribution. In men, as testosterone declines with age
[53] and in polycystic ovary syndrome (PCOS) women, often character-
ized by a hyper-androgenic state [54,55] (reviewed in [56]), there is an
increase in VAT. Testosterone therapy in aging men decreased visceral
fat mass and increased lean muscle mass [57,58]. In women, testoster-
one levels correlated positively with signiﬁcantly increased abdominal
fat [59,60]. In addition, obese postmenopausal women treated with
testosterone developed signiﬁcantly increased visceral fat [61,62].
Numerous studies have demonstrated that both SAT and VAT in
men and women express sex steroid receptors, notably the estrogen
(ERα, ERβ and its variants, and G protein-coupled ER) and androgen
(AR) receptors [63–66]. There is also limited evidence to support
regional and sex differences in the expression of sex hormone recep-
tors. ERβ1 expression (mRNA and protein) was much reduced in VAT
(intra-abdominal) compared to SAT, whereas the expression of ERβ4
and ERβ5 mRNA levels was signiﬁcantly higher in gluteal SAT com-
pared to abdominal SAT in both men and women, with higher ERβ
mRNA levels in women compared with men [67]. Recent ﬁndings
by Gavin et al. support these results, as their analyses demonstrate
that abdominal SAT contained more ERα protein compared to gluteal,
and gluteal SAT contained more ERβ protein when compared to
abdominal SAT from overweight premenopausal women collected
during the follicular phase of the menstrual cycle [68]. Importantly,
the waist-to-hip ratio negatively correlates with the gluteal ERβ pro-
tein abundance and positively with the ERα/ERβ ratio, indicating that
ERs play a role in modulating regional fat distribution. In addition,
ERα and ERβ have been reported to mediate distinct, depot-speciﬁc
actions [66,67,69]. Estrogens in vitro up-regulate the expression of
both ERα and ERβ mRNA in subcutaneous adipocytes from women,
but only the ERα in subcutaneous and visceral adipocytes from men
[66,67,69]. In addition, though the ERα subtype was present in
preadipocytes, estrogens in vitro regulated the ER activity in differen-
tiated but not in conﬂuent preadipocytes, suggesting that the ER be-
comes functional during the course of adipogenesis [66,67,69].
Investigations utilizing knockout models have also yielded novel in-
formation regarding the speciﬁc roles for estrogen, as well as ERαand ERβ, in the maintenance of WAT lipid and glucose homeostasis
[70–73] (reviewed in [74]). Hence, these studies provide evidence
that estrogen may modulate fat accumulation in a depot-speciﬁc man-
ner via the differential expression of ERs within WAT.
Sex-speciﬁc adipose tissue distribution may also result from the se-
cretion of sex hormones from adipose tissue in a depot-speciﬁcmanner.
Though other tissues account for themajority of sex hormones in circu-
lation, adipose tissue can also contribute a substantial amount of circu-
lating estrogen and testosterone (reviewed in [75,76]). Furthermore,
human WAT depots possess the enzymes and intermediates necessary
for sex hormone synthesis in a depot-speciﬁc manner (reviewed in
[77,78]). Collectively, these data suggest that both circulating and
local adipose tissue production of sex hormonesmay have important ef-
fects on adipose tissue distribution (reviewed in [79]). Further studies
are necessary to elucidate the regional effects of sex-steroid hormones
in adipose tissue. Determining the expression of steroidogenic metabo-
lizing enzymes and ERs in upper- and lower-bodyWAT and testing the
effects of treatmentwith sex steroids on the cellular dynamic properties
of preadipocytes in both sexes will further advance our understanding
of the contribution of sex hormones to WAT metabolism.
3. Adipogenesis
3.1. Deﬁnition
Although most development occurs during prenatal and early
postnatal life (reviewed in [80]), WAT retains the ability to expand
during adult life, especially to accommodate energy surplus. Adipose
tissue expansion (adipogenesis) occurs in two ways — by increase of
existing adipocytes' size (hypertrophy) or by recruiting new fat cells
(hyperplasia). The mechanisms that inﬂuence the pattern of expan-
sion via hypertrophy and/or hyperplasia have not been elucidated,
as individuals vary by the predominant depot-dependent cellular
mechanisms that are involved. Preliminary evidence in rodents sug-
gests that VAT (perigonadal) expands predominantly by adipocyte
hypertrophy, while SAT (inguinal) by adipocyte hyperplasia follow-
ing exposure to a high-fat diet [81]. Findings from Tchoukalova et
al. have shown that SAT expansion in response to overfeeding
resulted in higher adipocyte hypertrophy in the upper-body (abdom-
inal) SAT depot, relative to femoral SAT depot, which had increased
hyperplasia [82]. Indeed, adipocyte morphology is signiﬁcant, as in-
creased adipocyte size correlates with higher metabolic risk [83–85].
Accumulating evidence in human subjects suggests that obesity com-
plications result from the inability of SAT to expand and safely store
lipids, which leads to ectopic deposition in other tissues, lipotoxicity,
and insulin resistance (reviewed in [86–90]). We have shown that the
number of small, early-differentiated adipocytes, isolated from the stro-
mal–vascular fraction (SVF) in SAT depots of normal weight men and
women, correlates positively with subcutaneous adiposity (particularly
in the femoral SAT), and negatively with the visceral fat accumulation
[91]. These data indicate that the abundance of adipocytes in the SAT
depots is an important predictor for SAT expandability. The aforemen-
tioned studies highlight the importance of proliferative adipocyte pre-
cursor cells that are capable of undergoing differentiation to supply
new, mature adipocytes, in order to support the expansion of SAT,
prevent the accumulation of fat in VAT, and maintain healthy adipose
dynamics. Therefore, to safely accommodate metabolic demands, an
adipocyte precursor pool is thought to remain present and undergo a
constant cell turnover in WAT during adult life. Studies by Spalding
et al. suggest that approximately 10% of the body's adipocytes are
regenerated each year [92]. In addition, adipocyte number can increase
during the development of obesity in adulthood, despite a higher rate
of apoptosis (cell death) [93]. Although the term adipogenesis refers to
the proliferation and differentiation of adipocyte precursor cells, the
apoptosis of adipocytes and their precursors is an important regulator
of adipocyte cellularity and is, thus, also mentioned in this section.
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Very few in vivodata is available regarding themechanisms thatmod-
ulate the commitment of adipocyte precursor cells to the preadipocyte, as
well as the processes that control the formation of new adipocytes in
human WAT. The established approaches to assess adipogenesis in
WATdepots involve observing the changes in adipocyte size and/or num-
ber or analyzing fat cell size distribution, accompanied by the expression
proﬁles of proteins or genes involved in adipogenesis [94,95]. Alternative
methods include functional assays and immunohistochemistry to deter-
mine adipocyte differentiation, proliferation, and susceptibility to apo-
ptosis, using preadipocyte cell lines or primary adipose-derived stem
cell cultures (reviewed in [96,97]). These techniques have been invalu-
able in providing data regarding various facets of adipogenesis and in
identifying proteins or pathways that regulate adipogenesis. However,
these in vitro techniques show limited snapshots of select mechanisms
of adipogenesis and cannot provide an integrative evaluation of
adipogenesis within the natural microenvironment of the adipose
tissue.
Additional studies designed to overcome these limitations have
been performed by investigators using animal models, in which adipo-
cyte size-distribution analyses were taken at the end of high-fat dietary
interventions with gradually increasing durations to show the dynam-
ics of adipocyte cellularity with weight gain, using a cross-sectional
design [93] or obtained longitudinally by serial biopsies of inguinal
WAT depots [98]. Collectively, these studies suggest an oscillatory
pattern of adipose tissue remodeling, involving simultaneous and re-
petitive cycles of hyperplasia, hypertrophy, and hypoplasia (decreased
adipocyte number), presumably reﬂecting proliferation and differentia-
tion of adipocyte precursor cells, development of mature adipocytes,
and apoptosis, respectively. Interestingly, the rate of enlargement of
adipocytes (hypertrophy) is proportional to the difference between
the lipid load and the storage capacity of adipocytes [98], which may
also depend on both the number andmetabolic properties of the adipo-
cytes. These ﬁndings correlate with other studies, which suggest that
the adipose morphology of SAT may be related to adipocyte turnover
[99], as subjects with hypertrophy generated 70% less adipocytes
per year than those with hyperplasia. Frequent cycling, however, may
promote replicative senescence of adipocyte progenitor cells and im-
pairment of their adipogenic function [100]. Though these approaches
could yield valuable information, they are not applicable to study
human subjects due to the ethical consideration of their invasiveness.
Recently, Spalding and colleagues introduced an innovative method
to study adipocyte turnover in humans bymeasuring the incorporation
of 14C derived from above ground nuclear bomb tests in adipocyte DNA
[92]. Though the lipid turnover rates calculated by this method are reli-
able, the 14C-labeling method involves the retrospective analysis over a
long period of time (years). However, an additionalmethod, which em-
ploys labeling of DNA of adipocytes and the SVF with the stable isotope
deuterium (2H) over a short period of time (months), offers an advan-
tage to study in vivo adipogenesis [101]. Our laboratory has reﬁned
this method in a rat model by purifying the isolated adipocytes and
adipocyte progenitor cells (short-time culturing of SVF) [102]. Impor-
tantly, this method provides an advantage over the in vitro techniques
for assessment of adipogenesis, as it provides an integrative evaluation
of adipogenesis within the natural microenvironment of the adipose
tissue, which can also be utilized for intervention studies due to the
shorter duration of time. Overall, this method has valuable implications
to assess cell turnover in adipose tissue [103]; however, the effective-
ness of this method to study human adipogenesis and adipocyte cell
turnover in vivo remains to be validated.
3.3. Depot-dependent differences in adipogenesis
While numerous studies have investigated regional differences in ad-
ipose tissue metabolism, few have examined depot-speciﬁc differencesin adipocyte differentiation [104–107]. WAT depots possess signiﬁcant
differences in adipogenesis, as the proliferation and differentiation of
both human and rodent primary preadipocytes have been shown to be
inﬂuenced by the anatomic location of the depot, as well as aging,
gender, and metabolic health [82,89,108–118]. While the differences in
adipogenesis and its regulation in SAT and VAT depots have been exten-
sively studied [104,105,119], studies comparing adipogenesis between
upper-body and lower-body subcutaneous depots are sparse [82,106].
Early studies using thymidine incorporation into fat cell DNA reported
increased proliferation in the visceral (parametrial and retroperitoneal
depots) preadipocytes of high fat diet-fed rats [120]. Additional studies
in rodents indicated that SAT (inguinal) adipocyte progenitors in ro-
dents are more abundant and have signiﬁcantly increased proliferation
as compared to VAT (perigonadal) adipocyte progenitors in response to
high-fat diet [81]. Notably, recent studies by Macotela et al. that high-
light the intrinsic differences of VAT (epididymal) versus SAT (inguinal)
preadipocyte pools in mice reveal that precursor cells from VAT display
less differentiation capacity, and VAT has a decreased percentage of
preadipocytes following high fat diet, with subsequent increase in
other stromovascular cells (i.e. macrophages). They also demonstrate
that preadipocytes from VAT highly express anti-adipogenic factors, as
opposed to preadipocytes from SAT, which show higher expression of
pro-adipogenic genes [121]. This decrease in the preadipocyte pool
may be partially attributed to increased cell death of adipocyte precur-
sor cells in VAT, as increased susceptibility to apoptotic stimuli of VAT
(vs. abdominal SAT) preadipocytes has been reported in human sub-
jects [122,123]. Early human studies from the Kirkland laboratory
revealed that preadipocytes from abdominal SAT accumulated more
lipids and had higher differentiation capacity and levels of adipocyte
markers compared to preadipocytes from VAT in obese subjects [119].
Other studies performed in primary cultures showed that the prolifera-
tion capacity of preadipocytes from abdominal SAT precursor cells
was higher than in VAT (omental) cells in obese individuals [105]. Over-
all, the reduced proliferation and differentiation capacity of visceral
preadipocytes may account for the increased hypertropy of existent
adipocytes and the metabolic abnormalities associated with VAT.
Accumulating evidence suggests that preadipocyte number and
cellularity may depend on the metabolic state of the individual.
Isakson et al. demonstrated impaired differentiation of preadipocytes
from abdominal SAT in obese individuals, when compared to lean
[87]. More recent reports showed that abdominal SAT has increased
proliferation of adipocyte precursors in increasing obese condi-
tions [124]. Collectively, these ﬁndings suggest that the preadipocytes
in the abdominal SAT depot of obese individuals have the capacity to
proliferate, in response to metabolic demand, but lack the ability to
differentiate. Conversely, other studies indicate that the preadipocyte
numbers were lower in obese women as compared to lean [88]. How-
ever, these observations could be attributed to greater recruitment of
preadipocytes to adipogenesis or greater preadipocyte apoptosis.
Recent ﬁndings demonstrate that humans with morbid obesity,
with corresponding excessive WAT development, had decreased
adipocyte precursors in abdominal SAT, compared to individuals
with moderate obesity [125]. This decrease was accompanied by
smaller mean adipocyte diameter and a marked increase in the ex-
pression of adipogenic markers, which suggests increased differentia-
tion of new preadipocytes and subsequent depletion of the adipocyte
progenitor pool. Indeed, recent compelling data reported decreased
replicative potential, premature cellular senescence, and loss of the
differentiation potential of VAT preadipocytes from patients with
morbid obesity compared to lean individuals [100]. Likewise, other
ﬁndings have shown that although thiazolidinediones stimulate
adipogenesis, its chronic administration decreases the adipogenic poten-
tial of adipocyte progenitor cells in WAT [126]. Hence, depot-speciﬁc
differences in adipocyte progenitor abundance and proliferation may
inﬂuence whether a fat depot expands by hypertrophy or hyperplasia,
and thus could also have important implications on the development
380 U.A. White, Y.D. Tchoukalova / Biochimica et Biophysica Acta 1842 (2014) 377–392of metabolic disease. Collectively, the aforementioned studies demon-
strate that, compared to VAT preadipocytes, the SAT preadipocytes
have higher proliferation and differentiation, but are less prone to
apoptosis. This suggests the existence of an adipocyte precursor pool
with a higher efﬁciency for adipogenesis that may contribute to a higher
contribution of hyperplasia in SAT than VAT in conditions of obesity.
Though the aforementioned data collectively indicate that SAT de-
pots contain a greater number of functional adipocyte progenitors as
compared to VAT depots, these ﬁndings are inconclusive; as additional
analyses of the adipose cellularity of lower-body depots are necessary.
Limited investigations indicate that preadipocytes from abdominal
SAT of obese women differentiate less readily and are more susceptible
to apoptosis as compared to the femoral SAT depot [88]. These results
support previous reports in primary cultures showing that abdominal
SAT preadipocyte differentiation inversely correlates with increased
obesity and central adiposity [127]. Thus, the stromavascular fraction
(SVF) of abdominal SAT fat tissue from centrally obese individuals
might containmore preadipocyteswith impaired differentiation poten-
tial compared to femoral SAT. This provides evidence that VAT and
abdominal SAT may share similar properties, as previously shown
[128].
3.4. Sex-dependent differences in adipogenesis
Limited studies depict sexual dimorphism in adipogenesis. Cross-
sectional comparisons of adipocyte morphology and adipogenesis in
abdominal and femoral SAT depots in men and premenopausal
women with normal weight show larger femoral vs. abdominal SAT
adipocyte size in both sexes, but more abundant small adipocytes
(aP2+CD68‐ population in the SVF) in women than in men, especially
in the femoral depot [91,129]. Interestingly, femoral adipocytes differ-
entiate less than abdominal SAT in vitro but are more resistant to
tumor necrosis factor alpha (TNFα)-induced apoptosis, suggesting
reduced turnover and utilization of the preadipocyte pool in lower- vs.
upper-body fat in women [91]. Thus, it appears that a contribution by
microenvironmental factors and the existence of a high abundance
of small adipocytes, rather than the inherent dynamic properties of
preadipocytes, may explain the higher percent of lower-body SAT in
women with normal weight.
With accumulation of adipose tissue in obesity, the number of
adipocytes increases in women but not in men [129] (Table 1).
While adipocyte size increases in both sexes, the rate of the adipocyte
hypertrophy is higher in men than in women, particularly in the
lower-body fat. Cross-sectional comparisons of adipocyte morphology
and adipogenesis in abdominal SAT and VAT depots in pre- and post-
menopausal women reveal adipocyte hypertrophy in both depots
but hyperplasia only in the abdominal SAT depot [130] (Table 1).
Although such comparisons have not been done solely inmen, the ﬁnd-
ings of reduced adipogenic capability of VAT preadipocytes compared to
abdominal SAT preadipocytes in studies of obesemen andwomen com-
bined and the larger visceral fat accumulation in men [91,131] suggest
greater contribution of adipocyte hypertrophy to the VAT expansion
in men than in women.
Because sex hormones are known regulators ofWAT function, there is
increasing evidence for the effects of sex steroids on preadipocyte kinet-
ics. For example, testosterone supplementation inhibits the commitmentTable 1
Dynamics of adipocyte characteristics and adipose tissue remodeling with fat gain by depo
Depots Females
Adipocyte size Adipocyte number Frequency of fat tissue remod
Omental ↑ ↔ ↑
SAT Abdominal ↑ ↑ ↑/↔
Femoral ↑ ↑↑ ↔
a Hypothetical interpretations; ↑, increased;↔, not changed.of pluripotent mesenchymal stem cells to the adipogenic lineage,
while promoting myogenesis [132]. Furthermore, testosterone im-
pairs adipogenesis of 3T3–L1 preadipocytes, via interaction of the
androgen-receptor complex with β-catenin in theWnt signaling path-
way [133]. Estrogen stimulates preadipocyte proliferation [134], via
non-genomicmechanisms involvingMAPK-dependent and c-fos signal-
ing pathways [135]. Themitogenic effect of estrogen is demonstrated in
both abdominal SAT and VAT preadipocytes; but women are more
responsive than men [136]. Estrogen increases adipogenesis via tran-
scriptional up-regulation of PPARγ and IGFR1 genes in ovariectomised
animals only [137]. Progestins stimulate preadipocyte differentiation
by increasing the gene expression of adipocyte determination and differ-
entiation 1/sterol regulatory element-binding protein 1 (ADD1/SREBP1)
transcription factor, which in turn up-regulates the transcription of the
lipogenic enzyme fatty acid synthase (FAS) [138]. More importantly,
the transcription of cytochrome P450, one of the components of aroma-
tase, is higher in the femoral than in the abdominal region SAT [139,140].
In addition, an analysis of the global gene expression in the VAT
(perigonadal) fat pads in male vs. female mice found that members of
the cytochrome 450 superfamily, including aromatase cytochrome
P450 (product of the Cyp 19 gene), and hydroxysteroid dehydrogenases
are among the sexually dimorphic genes [140].
Women have ﬂuctuations in their levels of sex hormones, which
can be modulated by the menopausal status, the use of contraceptives
in premenopausal women, or the receipt of HRT in peri- or post-
menopausal women. Therefore, these factors must be considered
when formulating a study design to effectively analyze WAT, as sex
hormones are effectors of adipose metabolism. Nevertheless, the
aforementioned studies included women that took contraceptives
[91] and postmenopausal women [130], and additional analyses ex-
cluding these women did not change the main results or conclusions
of the study.
3.5. Summary
Overall, in vitro analyses have provided limited, yet very useful
information on the processes of adipocyte turnover. Analyzing the var-
ious aspects of adipocyte morphology and adipogenesis (Table 1) will
contribute to a greater understanding of factors that inﬂuence depot-
and sex-speciﬁc WAT expansion. Recent research investigations have
integrated the complex dynamics of adipocytemorphology and adipose
tissue remodeling in relation to other aspects of WAT function. An
overview of the differences in adipose tissue remodeling cycles among
depots in men and women that is based on current published data is
suggested in Table 1. The general hypothesis is that the high rate of
adipocyte hypertrophy and low contribution of hyperplasia in WAT
predispose some individuals to increased susceptibility to apoptosis,
increased initiation of a local inﬂammatory response (inﬁltration of
adipose tissue with immune cells and increased secretion of pro-
inﬂammatory molecules by immune cells and adipocyte precursor
cells) [141], and gradual impairment of the adipogenic potential of ad-
ipocyte precursor cells [100]. In effect, these events shorten the cycles
leading to unfavorable increase in their frequency. Taking into account
the depot-differences in adipogenesis and adipocyte morphology, it
appears that VAT may be more susceptible to this detrimental adipose
remodeling than the SAT depots in both sexes. In addition, the moret and sex.
Males
elinga Adipocyte size Adipocyte number Frequency of fat tissue remodelinga
↑↑↑↑a ↔a ↑↑↑
↑↑ ↔ ↑
↑↑↑ ↔ ↑↑
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available small adipocytes having high lipid storage capacity may
cause accelerated adipose tissue remodeling and subsequent adipose
dysfunction in men. In contrast, in SAT depots in women, these cycles
may be insigniﬁcantly affected, and the local inﬂammation accompany-
ing the adipocyte hypertrophy may be successfully resolved without
any unfavorable functional consequences. Because WAT remodeling
and metabolism are very complex, future analyses should involve the
assessment of adipogenesis in vivo, in order to integrate factors within
the naturalmicroenvironment of the adipose tissue that are not present
in vitro.
4. Developmental programming of regional adipose tissue function
Transcriptional proﬁling has revealed limited yet valuable informa-
tion about potential genetic determinants and intrinsic mechanisms
that underlie the depot-speciﬁc characteristics of adipose tissue in
both men and women. Differences in the expression of developmental
genes, many of which are highly conserved transcription factors that
act during normal development and remain active in adults, have been
reported in the adipose tissue of rodents and humans [142–147]. One
large group of developmental genes contain a particular DNA sequence
(homeobox) coding for a distinguishable but variable protein domain
of approximately 60 amino acids (homeodomain) [148]. Genes
encoding proteins with similar sequences within the homeodomain
are categorized into eleven classes [148]. One interesting family of 39
members that contains the homeodomain sequence from Class 1 is
the HOX genes. They are organized in four clusters of 9–11 genes local-
ized on chromosomes 7 (HOXA), 17 (HOXB), 12 (HOXC), and 2 (HOXD).
Genes in the four clusters with similar sequences and position on the
locus can be aligned with each other into 13 paralogous group, which
are organized along the chromosome in an order that parallels their ex-
pression along the anterior-posterior body axis in chronological order
[149]. Speciﬁcally, 3′ HOX genes in groups 1–3 are expressed earliest
during development and primarily control the rostral body segments,
followed by the expression of the central HOX genes in groups 4–8,
which control the thoracic portion of the body, and ﬁnally by the 5′
HOX genes in groups 9–13 that control the lumbo-sacral region. This
approach, deﬁned as spatial and temporal co-linearity, enables the
HOX genes to convey regional body patterning. Other families of
homeodomain proteins, found to be expressed in adipose tissue include
Irx (iroquois), hedgehog (Hh), engrailed (En) genes, paired related
homeobox (Prrx), Meis homeobox 1 (Meis), pre-B-cell leukemia ho-
meobox I (Pbx), PBX/knotted homeobox (Pknox), short stature homeo-
box (Shox), and others. T-box (TBX) genes are a family of genes
encoding transcription factors that are different from the homeodomain
proteins, but also regulate a variety of developmental processes and are
expressed in adipose tissue.
4.1. Depot-dependent differences in the expression of developmental genes
Studies comparing SAT (inguinal in mice and abdominal SAT in
humans) and VAT (epididymal in mice and omental in humans) reveal
that adipose tissue from VAT expresses higher levels of HOXA5 and
HOXC8, whereas SAT has higher levels of HOXA10, SHOX2, and EN1,
in both mice and humans [104,142–144]. Conversely, TBX15 and
Sfrp2 were higher in SAT vs. VAT in mice, but higher in VAT vs. SAT in
humans [144]. In addition, microarray analyses identify that gluteal
SAT, adipocytes and the SVF express lower levels of HOXA2, HOXA3,
HOXA4, HOXA5, HOXA9, HOXB7, HOXB8, HOXC8, and IRX2, but higher
levels of HOXA10, HOXC13, and PBX15 compared to those from the
abdominal SAT site [146,147]. Notably, depot-speciﬁc variations in
gene expression are also observed in preadipocytes [104,144]. In addi-
tion, select developmental genes, TBX15 and HOXA5, demonstrate
changes in expression that correlate with levels of obesity (body mass
index) and fat distribution (waist-to-hip ratio) [144]. More extensivegene expression analyses reveal that homeobox genes and other
pregnancy-associated factors, are distinct between fat cell progenitors
of both rodent and human adipose tissue depots [104,150,151]. The
observed differences in gene expression appear to be intrinsic and per-
sist through in vitro culture and differentiation; hence, the microenvi-
ronment does not appear to be an inﬂuence. Furthermore, the results
from the aforementioned experiments by Tchkonia et al. highlighting
the differences in lipid accumulation and differentiation capacity of ab-
dominal SAT versus VAT preadipocytes [119] were associated with
distinct patterns of gene expression and conserved over multiple
cell generations [145]. Collectively, these data suggest that WAT de-
pots originate from different precursor cells, whose function is pre-
sumably controlled by genes involved in development and pattern
speciﬁcation.
Questions arise as to the regulatory mechanisms that drive the
homeobox gene expression. Recently, several hormones and their
cognate receptors that inﬂuence adipogenesis have been shown to
regulate select homeobox gene expression. For example, retinoic
acid has a well-characterized role in the commitment of mouse
embryonic stem cells to the adipocyte lineage [152]. Interestingly,
PBX1 has been shown to be induced after following treatment with
retinoic acid suggesting its involvement in mediating the retinoic
acid action [152]. A siRNA-mediated silencing of PBX1 expression
in multipotent adipose derived stem cells (hMADs) demonstrates
that PBX1 may play a role in human adipogenesis by maintaining
the proliferation of adipocyte precursors and preventing their com-
mitment to the adipocyte lineage [152]. Recently, the expression of
PBX1 and PBX3 has been shown to be higher in abdominal SAT com-
pared to gluteal depots [146]. Taken together, these data suggest that
the depot-speciﬁc differences in preadipocyte pools are established
during development.4.2. Sex-dependent differences in the expression of developmental genes
Sex differences in the expression of homeobox genes have also been
observed in adipose tissue. Gesta et al. reports that there is higher
expression of the HOXC9 gene in SAT than in VAT in males, but not in
females [144]. Genome-wide association studies (GWAS) and meta-
analyses of GWAShave also identiﬁed novel sexually-dimorphic genetic
loci associated with upper- or lower-body fat distribution [153,154],
including ﬁve genes (RSPO3, TBX15, ITPR2, WARS2 and STAB1) that are
differentially expressed between abdominal and gluteal SAT [153].
These studies provide evidence for sexual dimorphism in the associa-
tions of certain genetic loci as effectors of adipose tissue distribution.
Sex differences in epigenetic regulation by environmental and/or
hormonal factors have been reported in both rodents and humans and
greatly contribute to adipose tissue distribution [155]. Polymorphisms
in the estrogen receptor α gene are also associated with body fat distri-
bution in women [156,157].
A recent transcriptional study of the homeobox genes in abdomi-
nal and gluteal SAT depots in men with abdominal obesity (WHR
0.91) and premenopausal women with more peripheral fat distribu-
tion (WHR 0.82) shows that the expression of HOXC13 and HOXB8
in the gluteal depot is higher in females than in males, whereas the
expression of the HOXA2 gene is higher in males compared to females
[146]. The expression of the homeobox gene cofactors PBX1, PBX3,
and MEIS 1 is higher in abdominal SAT compared to the gluteal
depots only in male subjects [146]. Sex hormones, including estrogen,
progesterone, and testosterone, have also been described to regu-
late homeobox gene expression and mediate diverse functions in
both developing and adult tissues (reviewed in [158]). These data
further support the notion that the apparent differences in adipose
tissue function between obese males and females may be mediated
by sex hormones via downstream regulation of homeobox gene
transcription.
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Because developmental genes heavily inﬂuence cell fate and may
regulate the development of WAT in utero, their role in nutritional
reprogramming of regional adiposity in both sexes requires further in-
vestigation. Given the evidence of their differential expression in adult
adipose tissue among depots and between sexes, future studies are
warranted to explore the precise role in the regulation of regional
WAT expansion and fat distribution. Speciﬁc directions are well delin-
eated by Karastergiou and colleagues [159] and include: 1) to validate
whether the depot- and sex differences in developmental genes are
retained after ex vivo culture; 2) to understand the importance of
developmental genes in regulating adipogenesis and the functional
properties ofmature adipocytes; 3) to determinewhether other cellular
types from the SVF also exhibit depot-dependent differential gene ex-
pression and, if so, to understand the subsequent effect on themicroen-
vironment; 4) to investigate whether fat distribution has contributed to
the differences in gene expression proﬁles found between men and
womenwith peripheral fat distribution, by performing additional com-
parisons between men and women with the same (upper-body) fat
distribution phenotype or between women with upper- vs. lower-body
fat distribution; and 5) to determine whether depot differences in HOX
gene expression contribute to racial differences in fat distribution.
5. Secretory function
An important property of adipose tissue is the production of
secretory factors (adipokines) that mediate local and whole body me-
tabolism via auto-/paracrine and endocrine mechanisms. Adipose tis-
sue expansion, and subsequent remodeling, is often associated with
altered adipokine production. Several WAT-derived factors have
been investigated and shown to modulate numerous physiological
systems. Notably, many adipokines are also up-regulated in obesity
and promote inﬂammatory responses, insulin resistance, and other
metabolic complications (reviewed in [160]). Evidence suggests
that variances in adipokine secretion may partly contribute to the
differential metabolic risks that are associated with fat distribution,
notably the protective properties of lower body WAT (reviewed in
[24]).
Leptin, an adipocyte-secreted factor, was shown to be predomi-
nantly expressed by isolated subcutaneous adipocytes as opposed to
omental adipocytes, particularly in women [161,162]. In vivo human
studies demonstrate that secreted levels of leptin are higher in femo-
ral SAT than abdominal SAT [163]. Another metabolically favorable
adipokine, adiponectin, was shown to be positively associated with
femoral SAT and gluteal fat mass [164,165] and negatively associated
with VAT [166]. Interestingly, levels of both leptin and adiponectin
are higher in women [167–171].
Other adipokines have been shown to be highly regulated in obesity/
T2DM and may contribute to metabolic dysfunction. Retinol-binding
protein 4 (RBP4), a protein released from adipocytes and associated
with obesity and insulin resistance, is preferentially produced by VAT
and is a marker of intra-abdominal adipose tissue expansion [172].
Plasminogen activator inhibitor 1 (PAI1), an inhibitor of ﬁbrinolysis, is
strongly up-regulated in VAT depots, and plasma levels correlate with
trunk fat mass in obesity [173], suggesting a plausible link between
obesity and thrombotic disorders [174].
5.1. Novel adipokines
In recent years, several novel adipokines have been identiﬁed
and are at the forefront of scientiﬁc research to elucidate their
roles in human metabolism and disease. Here, we present the cur-
rent state of the knowledge of selected adipokines (summarized
in Table 2).5.1.1. Dipeptidyl peptidase (DPP)-4
Protein expression of dipeptidyl peptidase (DPP)-4, a novel adipokine
previously studied for its role in the incretin system, is substantially
elevated in VAT compared with SAT of obese individuals [175]. The
main cellular source of DPP4 secretion is differentiated adipocytes,
with a lesser contribution from SVF cells and macrophages. DPP4
mediates insulin resistance, as this adipokine decreases insulin action
in adipocytes via decreased insulin-stimulated Akt phosphorylation.
Serum levels of DPP4 are also elevated in obese subjects, compared to
subjects with normal weight, and are highly associated with abdominal
SAT adipocyte hypertrophy, insulin resistance, and other components of
the metabolic syndrome.
5.1.2. Chemerin
Chemerin, also known as retinoic acid receptor responder 2
(RARRES2) or tazarotene-induced gene 2 (TIG2), is another recently
discovered adipocytokine that may inﬂuence adipose tissue develop-
ment, inﬂammation, and glucose homeostasis [176]. It is synthesized
as an inactive precursor, prochemerin, which is converted to its active
form through C-terminal cleavage by serine proteases, especially during
inﬂammatory conditions. Chemerin signals through the G-protein
coupled seven trans-membrane receptors ChemR23 (CMKLR1) [177]
and G protein-coupled receptor 1 (GPR1) [178]. Evidence also suggests
that chemerin binds to the C–C chemokine receptor-like 2 (CCLR2),
which seems to increase its local concentration and facilitate its presen-
tation to ChemR23 on adjacent cells [179,180]. CMKLR1−/−mice exhibit
decreased adipose tissue TNFα and IL-6mRNA, but are glucose intolerant
compared with wild-type mice due decreased glucose-stimulated insu-
lin secretion and glucose uptake in skeletal muscle and WAT [181].
Both adipocytes [182] and ﬁbroblasts [183] produce chemerin. Adipo-
cyte hypertrophy and the inﬂammatory microenvironment in adipose
tissue enhance chemerin synthesis, as judged by its increased secretion
in response to free fatty acids, lipopolysaccharide, and interleukin-
1beta [184,185]. Chemerin acts like a chemokine in that it induces
leukocyte migration and increases macrophage adhesion to VCAM-1
and ﬁbronectin [186], and thereby potentiating local inﬂammation. In
contrast, it also exerts potent anti-inﬂammatory effects on activated
macrophages by promoting phagocytosis [187]. It is not clear whether
these dual actions are elicited by different chemerin variants; hence,
these effects require further analysis and validation.
Obese subjects with metabolic syndrome have elevated levels of
circulating and gluteal SAT-secreted chemerin [188]. In addition,
circulating chemerin levels are positively correlated with VAT accu-
mulation [189] and low circulating estradiol concentrations [190].
Moreover, measurements of the chemerin expression in paired ab-
dominal SAT and VAT samples in patients with severe obesity reveal
higher levels in VAT than in abdominal SAT in men, but the opposite
is observed in women. Interestingly, women with PCOS show a
pattern similar to men, suggesting a role of androgens in the sexual
dimorphism in adipose tissue-derived chemerin secretory function
[191]. Similar sex- and adipose tissue depot-speciﬁc differences in
chemerin mRNA expression levels are also reported by Alfadda A et
al. [192], with expression signiﬁcantly higher in women than men
and in abdominal SAT than VAT. Interestingly, they show a signiﬁcant
negative correlation between chemerin mRNA expression in abdom-
inal SAT and circulating chemerin levels, which in this study are
associated with obesity markers but not with markers of insulin resis-
tance. Apparently, the auto-/paracrine and endocrine mechanisms of
chemerin that regulate adipose tissue function and glucose homeo-
stasis is depot-speciﬁc. Further studies of the chemerin transduction
pathways in different adipose tissue depots are warranted to unravel
these distinct mechanisms.
5.1.3. Lipocalin 2
Lipocalin 2 (also known as neutrophil gelatinase-associated lipocalin
and 24p3) belongs to the lipocalin protein superfamily (reviewed in
Table 2
Notes on depot- and sex-dependent differences in the expression of novel adipokines.
Molecule Cellular sources in
AT
Auto/paracrine function Depot-speciﬁc
effects
on mRNA levels
Sex-speciﬁc effects on circulating
or AT mRNA levels
Effects of obesity
DPP4 Adipocytes(COR(+)
size) SVFMφ
↓Insulin signaling in
adipocytes
VAT > SAT in
obese
↑Serum DPP4
↑DPP4 mRNA in VAT, SAT
Chemerin SVF Adipocytes Pro-/anti-inﬂammatory SAT COR(−)
serum chemerin
M, F (PCOS): VAT > SAT
F: SAT > VAT
Serum chemerin COR(−) serum
estradiol
↑Secretion by hypertrophic adipocytes &
inﬂammatory AT
Lipocalin
2
Transports lipophilic
substances
(retinoids, steroids,
arachidonic acid)
M, F (PCOS): VAT > SAT
F: SAT > VAT
SAT COR(−) serum lipocalin 2
↑Secretion by Serum levels & relation to
insulin
sensitivity- varying data
Gpc4 Adipocytes
SVF (less)
↑Insulin signaling
↑Adipocyte differentiation
SAT > VAT in
lean
Serum Gpc4:
F: ↑ continuously with ↑BMI
M: ↑ from normal weight to
overweight but ↓ in obese
↑VAT, COR(+) BMI, WHR
↓SAT, COR(−) BMI, WHR
Serum Gpc4: COR(+) BMI, IR
Omentin SVF ↑Glucose uptake by
adipocytes
Anti-inﬂammatory
VAT > SAT AT mRNA: F = M Serum omentin COR(−)
serum testosterone
↓Serum & gluteal mRNA
Serum omentin:
COR(−) MetS
SFRPs SAT explant
secretes
SFRP1,-2,-4
↑Adipogenesis SFRP1:
anti-inﬂammatory,
↑adiponectin SFRP2-4:
inverse to SFRP1
Serum SFRP5: F > M SFRP1 mRNA: ↓SAT,↔VAT
SFRP2-4 mRNA: ↑SAT,
↑↑ VAT
Serum SFRP5: varying data
Vaspin Adipocytes
& precursors SVF
↑Glucose uptake by
adipocytes
Anti-inﬂammatory
↑Adiponectin
VAT: COR(+) BF
SAT: COR(+) IR &
WHR
AT mRNA: F = M
Serum vaspin: F > M
No mRNA in AT in lean
↑Compensatory with ↑BF, IR
Abbreviations: AT, adipose tissue; DPP4, dipeptidyl peptidase 4; SVF, stromal-vascular fraction; Mφ, macrophages; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue;
COR(+)/(−), positive or negative correlation; M, male(s); F, female(s); F (PCOS), women with polycystic ovary syndrome; Gpc4, Glypican 4; BMI, body mass index: body weight
(kg): height (cm)2; WHR, waist to hip (circumferences) ratio; IR, insulin resistance; MetS, metabolic syndrome; SFRPs, a family of ﬁve secreted frizzled-related proteins; BF,
body fat; ↑, increased; ↓, decreased.
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retinoids, arachidonic acid and steroids but the high-afﬁnity endoge-
nous ligands of lipocalin 2 are unknown. Circulating lipocalin 2 levels
are positively associated with adiposity, but metabolic endotoxemia
and consumption of saturated fat may inﬂuence their levels [194].
Involvement of this and possibly other factors could explain the
variable lipocalin-2 levels in the circulation of women with PCOS,
an insulin resistant state, that are found to be reduced [195], normal
[196], or increased [197] compared to healthy women. Likewise,
lipocalin 2-deﬁciency in mice is reported to either improve [198] or
impair [199] insulin sensitivity compared with control littermates
in the context of diet-induced obesity. The expression of lipocalin 2
in adipose tissue increases with obesity by inﬂammatory stimuli
[200–204]. There are sex- and depot-dependent differences in the
expression of lipocalin 2 that resemble those of chemerin; i.e. men
have higher expression of in VAT than in abdominal SAT, whereas
women showed the opposite [191]. Further studies are needed to
understand how these differences contribute to the distinct regional
adipose tissue function and whole body glucose homeostasis.
5.1.4. Glypican-4 (Gpc4)
The cell surface proteoglycan glypican-4 (Gpc4) was shown
to be released primarily by adipocytes, following a proteolyticTable 3
Relative alterations in adipokine transcription as a function of regional fat gain in men and
Depots Females
Pro-inﬂammatory Anti-inﬂammatory Compensatory anti-inﬂamm
VAT ↑ ↑↑ ND
SAT Abdominal ↑/↔ ↑/↔/↓ +
Femorala ↔ ↔ ++
a Hypothetical interpretations; ND, not detected; ↑, increased; ↓, decreased;↔, not chancleavage of the GPI anchor by lipases, such as the
insulin-regulated glycosylphosphatidylinositol-speciﬁc phospholi-
pase D (GPLD1). Glypican-4 expression is higher in abdominal SAT ver-
sus VAT depots in humans with normal weight [144]. Conversely, with
increasing body mass index (BMI) and waste-to-hip ratio (WHR),
Gpc4 mRNA levels in abdominal SAT decrease while those in VAT in-
crease, reaching the highest abundance in overweight and obese indi-
viduals [205]. In women, serum Gpc4 levels continuously increase
from the lean to the obese phenotype. While in men, serum Gpc4 in-
creases from the lean to overweight phenotype, but in obese men,
Gpc4 levels decrease to those observed in leanmen, possibly due great-
er reduction of GPLD1 activity as a result of enhanced insulin resistance
[205]. Overall, circulating Gpc4 levels positively correlate with increas-
ing BMI and insulin resistance, and additional experiments depict
glypican-4 as a novel adipogenesis-promoting and insulin-sensitizing
adipose-derived factor [205].
5.1.5. Omentin
Omentin is another new adipocytokine that is secreted mainly by
stromavascular cells [206]. Circulating omentin levels are reduced
in subjects with obesity and T2DM compared with lean subjects
[207–209] and lower omentin mRNA levels in gluteal adipose depot
have been reported in obese subjects with metabolic syndromewomen.
Males
atory Pro-inﬂammatory Anti-inﬂammatory Compensatory anti-inﬂammatory
↑↑↑↑ ↑ ND
↑ ↓ +/ND
↑↑ ↓↓ +/ND
ged.
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SAT [191,210] in both men and women, despite the putative andro-
gen response elements in its promoter region suggesting that other
factors may be involved in the regulation [191]. A recent study ﬁnds
sex as one of the determinants of circulating omentin concentrations,
and low testosterone concentrations are related to higher omentin
levels [190]. Omentin increases glucose uptake by human adipocytes
in vitro through enhanced protein kinase B (AKT) phosphorylation
and insulin signal transduction [209]. It also exerts anti-inﬂammatory
effects by inhibiting TNFα-induced expression of adhesion molecules
in endothelial and vascular smooth muscle cells [211,212]. These data
suggest that omentin may play a positive role to reduce inﬂammation
and increase insulin sensitivity, but its clinical relevance needs to be
conﬁrmed in future studies.
5.1.6. Secreted frizzled-related proteins (SFRPs)
A family of ﬁve secreted frizzled-related proteins, termed SFRP1-5,
has been implicated in the regulation of adipogenesis. They share signif-
icant homology with the Frizzled receptors and bind to wingless-type
(Wnt) ligands, interfering with the Wnt/β-catenin signaling [213],
which exerts adipogenesis-inhibitory action by reducing the expression
of pro-adipogenic transcription factors [214]. SFRP1 and SFRP4
mRNA is up-regulated during adipogenic differentiation, suggesting
a proadipogenic role [215,216]. A comprehensive assessment of all
ﬁve SFRP proteins in abdominal SAT and VAT depots from lean and
obese people in a study by Ehrlund A et al. [217] shows that distinc-
tive members of the SFRP family exhibit different depot-dependent
expression patterns as a function of obesity. Speciﬁcally, SFRP1 de-
creases in abdominal SAT but is unchanged in VAT, whereas
SFRP2-4 is up-regulated, more noticeably in the VAT depot, and
SFRP5 does not change in either depot. SFRP1 in abdominal SAT is
negatively associated with BMI and insulin resistance via reducing
the secretion of the proinﬂammatory cytokines and increasing the
release of adiponectin. SFRP2-4 mRNA levels in both abdominal de-
pots show opposite relationships, but the mechanisms are unknown.
Notably, SFRP1, SFRP2 and SFRP4 are secreted by abdominal SAT ex-
plants but not SFRP5, raising speculation about its contribution to the
SFRP5 in circulation. Furthermore, the reports on the role of circulating
SFRP5 in obesity-related insulin resistance are inconsistent. Some ob-
servations in animals and humans show that the levels decline with
obesity [218,219], while others report opposite ﬁndings [220,221]. It is
of interest to note that one study ﬁnds higher plasma SFRP5 levels in fe-
males compared to males, suggesting possible sex-speciﬁc regulation.
Additional studies are needed to elucidate the role of SFRP2-5 in the ad-
ipose tissue function, obesity, and metabolic health.
5.1.7. Vaspin
Vaspin (visceral adipose tissue-derived serine protease inhibitor,
serpinA12), is another adipokine associated with insulin-sensitizing
effects. In human studies, the vaspin mRNA levels are not detectable
in persons with normal weight and in some obese subjects with insu-
lin resistance. However, vaspin expression is induced in VAT and/or
SAT of overweight and obese individuals [222]. Administration
of vaspin to mice with dietary-induced obesity ameliorates insulin
resistance, in part, through normalizing the altered expression of
genes relevant to insulin resistance, including leptin, resistin, TNFα,
glucose transporter 4, and adiponectin [223]. Some studies suggest
that the induction of vaspin gene expression in human adipose tissue
may be a compensatory mechanism associated with obesity and insu-
lin resistance. The vaspin mRNA levels vary between VAT and SAT
depots, but its regulation appears to be depot speciﬁc. Its expression
in VAT is strongly predicted by percent body fat whereas insulin sen-
sitivity predicts the SAT vaspin mRNA levels. Interestingly, although
no sex-differences are observed for the vaspin expression in adipose
tissue, sexual dimorphism has been reported for circulating levels,
which were shown to be higher in women [224,225].5.2. Summary
Overall, there is limited knowledge about the roles of functionally
divergent WAT depots in human adipokine production. Nevertheless,
many adipokines have been shown to be differentially expressed and
secreted, as a function of adipocyte morphology, between WAT de-
pots, speciﬁcally abdominal SAT and VAT. Likewise, the relationship
between circulating levels of adipokines, their secretion from WAT
depots, as well as their endocrine effects, have been heavily evaluated
to understand their contribution to the development of obesity and
related metabolic disorders. It is important to discern whether these
adipokines appear as a compensatory reaction to increased metabolic
distress, i.e. adipocyte hypertrophy, in an effort to undergo normal
adipose tissue remodeling, or if they have a pathogenic role leading
to WAT metabolic dysfunction. Accordingly, select adipokines may
exert dual pro- or anti-inﬂammatory or insulin resistant or insulin sen-
sitive effects, relative to the adipocyte characteristics andWAT remodel-
ing paradigms. A speculative summary of the depot- and sex-dependent
differences in novel adipokine production is presented in Table 3.
Overall, cytokines that decrease adipocyte insulin resistance and show
pro-inﬂammatory actions, including DPP4, chemerin, and lipocalin 2,
appear to be produced more in VAT than SAT depots and more in men
than in women. This may result from their secretion from hypertrophic
adipocytes, macrophages, and/or adipocyte precursor cells in a more
inﬂammatory state, reﬂecting aWAT remodeling patternmore frequent
in VAT depots and in men (Table 1). While adipokines with insulin sen-
sitizing and/or anti-inﬂammatory properties, such as Gpc4, omentin,
and certain SFRPs, seem to increase mostly in the VAT (more in
women than men), in an attempt to ameliorate or resolve the local
inﬂammation, and increase much less or decrease in abdominal SAT
(less in women than men). Of note, vaspin, is not detected in many
subjects but may also be expressed as part of a compensatory mecha-
nism in response to the development of insulin resistance. Importantly,
although the expression of adipokines in lower-body SAT has not been
analyzed, we speculate that sex differences in the production will be
highly signiﬁcant, considering the differences in adipocyte cellularity
between the two SAT depots between the sexes (Table 1). Further
studies of the adipokine expression in upper- and lower-body depots
using longitudinal designs will be necessary to test these hypotheses.
Likewise, the characterization of sex- and depot-differences in the
expression and secretion of the numerous novel adipokines (reviewed
in [193,226]) will provide further insight into the paracrine and endo-
crine function of adipose tissue depots and the relationship to energy
homeostasis and metabolic health.
6. Lipid metabolism
A critical function of adipose tissue is the storage and release of
triglycerides (TGs) to provide energy in the form of fatty acids, to be
utilized during exercise, fasting, or starvation. Important factors in
adipose tissue fatty acid metabolism are the rate of TG storage, pri-
marily via lipoprotein lipase activity, and the rate of lipolysis, which
is potently regulated by insulin (fed state) and catecholamines
(fasted state) and results in the liberation of free fatty acids (FFAs)
as fuel to tissues and organs. Likewise, evidence suggests that
upper-body (subcutaneous and visceral) and lower-body fat depots
show distinct properties in the rates and amounts of lipolysis and
fatty acid uptake, and variations in these factors may be responsible
for the depot-speciﬁc characteristics of adipose tissue.
6.1. Lipolysis and FFA release from WAT
Numerous ﬁndings suggest that there is great heterogeneity in lipol-
ysis between adipose tissue depots of men and women. On average, ad-
ipose tissue lipolysis is substantially greater (~40%) in women than in
men, even though metabolic health is typically better in women. This
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utilization and disposal of FFA in women [227,228] (reviewed in [229]).
Studies have shown that upper-body adipocytes isolated from lean
males and females are highly responsive to lipolytic adrenergic stimula-
tion, as compared to lower body adipocytes [230–234]. Importantly,
these effectsweremore pronounced in females. Subsequent in vivo stud-
ies in lean individuals support these ﬁndings, in that catecholamine-
induced lipolysis is greater in upper-body than in lower-body SAT
depots [235–237]. In addition, both exercise-induced and prolonged
fasting-induced lipolytic activity was signiﬁcantly more marked in ab-
dominal than in gluteal–femoral SAT [238,239]. Furthermore, in obese
women, femoral SAT is less lipolytically active than upper-body fat
[14,240]. A recent study byGavin et al. demonstrates that premenopausal
overweight women perfused with estrogen had an increased lipolytic
response in abdominal SAT, while estrogen inhibited lipolysis in gluteal
SAT [241]. This study, among others, highlights the role of sex hormones
in body fat distribution [242,243], and suggests that estrogen may be
involved in the maintenance of the gynoid body fat distribution in
premenopausal women. Additional studies demonstrate that hormone
sensitive lipase (HSL), a key enzyme in lipolysis, is differentially
expressed between adipose tissue depots (reviewed in [244]), and the
rate of action of HSL is higher in the abdominal than the gluteal depot
[245]. Importantly, upper-body/visceral adipose tissue lipolysis from
both males and upper-body obese females were also shown to be more
resistant to the anti-lipolytic effects of insulin when compared to
non-obese or lower body obese adults [246–249]. Furthermore, FFA
concentrations aremuch greater in upper-body obese individuals follow-
ing a meal [14,250], supporting the notion that upper-body adipocytes
are more resistant to the anti-lipolytic effects of insulin. In contrast,
lower body adipocytes are more responsive to the anti-lipolytic effects
of alpha 2 adrenergic agonists and have lower responses to lipolytic
agonists (reviewed in [251]). Collectively, these studies suggest that
body fat distribution greatly inﬂuences lipolysis, as summarized in
Table 4.While the regulation of lipolytic processes in variousWATdepots
requires further investigation, studies suggest that the differential levels
of lipolysis, as shown in the above analyses, may be mediated, in part,
through a higher expression of lipolytic beta-adrenergic receptors in the
upper-body depot [252,253].
Sex dimorphism is also evident in these analyses, as abdominal
SAT in women greatly exceeds the lipolytic effects seen in men;
while femoral SAT had an increased lipolytic response in men but
not women [237,238]. Lipolysis was also much greater in women
compared to men following prolonged fasting [254]. Conversely, the
stimulation of lipolysis in VAT is much higher in men than women
[237,253].
FFAs that are released from stored TGs can be utilized as required
between meals and in the starved state; however, excess FFAs can
contribute to the adverse metabolic consequences of obesity by
ectopic fat accumulation in hepatic and peripheral tissues. Compared
with lean women, systemic FFA release in the fasting state is greater
in upper-body obese women, due to their higher fat mass [255]. Like-
wise, lipolysis-induced FFA release is greatly reduced in lower-body
obese women, such that the levels are comparable to non-obese
women. Studies have demonstrated that lipolysis of VAT increases,
relative to visceral fat mass, which results in the release of excess
FFAs into the liver via the portal vein in both obese men andTable 4
Schematic of WAT depot- and sex differences in lipid metabolism.
Depots Females
WAT depot mass Lipolysis/FFA release FF
VAT ↓ ↑ ↑
SAT Abdominal ↑ ↑↑ ↓
Gluteal ↑ ↓↓ ↑↑
Femoral ↑ ↓↓ ↑↑women, but more so in obese women [256]. It is well-established
that high levels of FFA can mediate insulin resistance in both muscle
[257,258] and liver [259,260]. Nevertheless, though VAT-derived
FFAs play an important role in abnormalities of hepatic function in
obese individuals [261–263], VAT may not be a signiﬁcant contributor
of FFAs to peripheral tissues. Hence, upper-body obesity is highly
associated with increased FFA release, and abdominal SAT, as opposed
to VAT, may be the primary source of excess systemic FFAs in both
men and women [14,240,247].
6.2. Storage and uptake of FFA in WAT
The storage of intracellular TGs in adipose tissue derived from
FFAs depends on the action of lipoprotein lipase (LPL) by adipocytes,
as this is the rate-determining step in the uptake of circulating
TG-FFA. Several studies have assessed the depot- and sex-speciﬁc
regulation of LPL. In early studies, LPL expression and activity were
shown to be higher in subcutaneous abdominal than in gluteal adipo-
cytes in non-obese men [264]. Conversely, the activity of LPL was
higher in gluteal–femoral adipocytes from non-obese women as
compared with the abdominal depot [264,265]. Additional studies
demonstrate that LPL activity is lower in VAT versus abdominal
SAT-derived adipocytes isolated from women, but higher in the VAT
depot in obese men [234,266]. Likewise, in non-obese or moderately
obese men, LPL expression and activity is higher in visceral than in
gluteal adipocytes [234]. Additional evidence demonstrates that
testosterone was able to suppress LPL activity in the femoral SAT of
men, contributing to abdominal fat accumulation [267], while other
ﬁndings suggest that testosterone does not affect LPL activity in
the thigh [268]. Other studies have also demonstrated the role of
sex hormones in modulating LPL activity and expression [269,270].
Taken together, these variances may be due to both sex-speciﬁc
differences and the complex post-transcriptional regulation of LPL
[271]. Nevertheless, it is likely that LPL expression and activity play
a critical role in sex-speciﬁc adipose tissue depot development and
function.
Depot- and sex-speciﬁc differences in the direct uptake of circulat-
ing FFA have also been described. Overall, short-term meal-derived
FFA uptake was shown to be greater in upper-body abdominal SAT
versus lower-body SAT in both lean and obese men and women,
with women storing more in SAT than men [268,272,273]. One
point of consideration is that the in vivo rate of FFA uptake in these
studies was measured per mass of the entire adipose tissue. There-
fore, uptake may be calculated as greater in SAT due to its larger fat
mass and actually similar or lower in visceral adipocytes when calcu-
lated per cell. Nevertheless, storage of meal-derived fatty acids per
gram of adipose tissue lipid following a high fat diet is greatly
increased preferentially in the gluteal–femoral SAT of women com-
pared to men [274]. In addition, studies have shown that femoral
SAT of women with lower-body obesity more efﬁciently takes up
meal-derived FFAs from circulation [275]. These regional differences
were not observed in men; therefore, the aforementioned studies may
partially explain sex-dependent body fat distribution, aswomen typical-
ly have more lower-body fat [265]. Conversely, evidence suggests that
the uptake of meal-derived FFA in the VAT depot is greater in lean
men than women [272,276]. There are also differences between theMales
A uptake WAT depot mass Lipolysis/FFA release FFA uptake
↑ ↑↑ ↑
↓ ↑ ↑
↓ ↓ ↓
↓ ↓ ↓
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the VAT than abdominal SAT depot, which was in turn greater than the
femoral SAT depot in obese men and women [277]. Furthermore, in
men, testosterone induces meal FFA uptake preferentially into
abdominal SAT and decreases uptake in VAT [268]. Hence, older men
with decreased testosterone develop more VAT.
In the postabsorptive state, lean men are much less efﬁcient at the
direct uptake of circulating FFA into the femoral as compared to the
abdominal SAT depot; while in obese subjects, direct FFA uptake is in-
creased speciﬁcally in the femoral depot of women [278]. Additional
studies support these observations, as Koutsari et al. show that
women had greater FFA storage than men in both abdominal and
femoral SAT in the postabsorptive state [279]. Notably, storage rates
were signiﬁcantly greater in femoral SAT than abdominal SAT in
women, whereas the opposite was true in men. The femoral SAT
depot of women was also shown to more effectively store FFA during
walking conditions, as compared to the abdominal SAT depot and
each SAT depot in men [280]. Collectively, these ﬁndings suggest
that direct adipose tissue FFA storage is signiﬁcantly greater in
women than men.
Overall, the upper-body abdominal fat depot may participate in
the short-term daily FFA handling and uptake the ﬂux of dietary
fatty acids (reviewed in [281]), while the lower-body gluteal–femoral
depot appears to exert its protective properties in long-term fatty
acid storage, especially in women (Table 4). Moreover, the storage ca-
pacity of gluteal–femoral WAT may inﬂuence the level of abdominal/
central adiposity, as supported by a recent study by Hernandez et al.
depicting the pattern of fat redistribution fat following liposuction
[282]. Though some studies suggest that the depot-differences in the
above ﬁndings may be attributed to LPL activity [276], additional stud-
ies are necessary to evaluate the mechanisms underlying FFA storage
in upper- and lower-body depots of men and women. Short- and
long-term fatty acid metabolism in both upper- and lower-body depots
has not been fully elucidated and requires further analysis.
7. Conclusions
Studies support the hypothesis that regional WAT development
and expansion greatly impact metabolic health, as fat in different
body locations exhibits distinct features and functional characteris-
tics. Additional evidence also highlights sexual dimorphism in adi-
pose tissue function, and there is evidence for a plausible role of sex
hormones, especially estrogen, in regional WAT function. Yet, the
mechanisms that control the regulation of fat distribution in both
males and females are poorly understood. Indeed, the inﬂuences of
adipose tissue depot- and sex-speciﬁc effects on adipocyte function, as
well as the relationship to metabolic health are not fully elucidated and
warrant further analysis. Numerous studies have described depot-and
sex-differences in adipose tissue metabolism, such as adipogenesis, the
expression of developmental gene signatures, fatty acid handling, and
secretory function. Though many of these analyses have focused on
the differences between upper-body SAT and VAT, recent investigations
have focused on elucidating the differences between upper-and lower-
bodyWATmetabolism, especially the beneﬁcial effects of gluteal–femoral
adiposity.
Investigations have provided limited information on the adipocyte
proliferation, differentiation, and remodeling processes that are in-
volved in WAT expansion (Table 1). Much remains to be learned about
the factors from the microenvironment that inﬂuence adipogenesis in
adipose tissue depots in both sexes, and how they subsequently contrib-
ute to regional fat distribution and metabolic health.
Various studies have yielded the discovery of novel gene loci that
are involved in the regulation of body fat distribution in both males
and females. Likewise, analyzing the expression patterns of these
sex- and depot-speciﬁc genes may also provide clues as to the mech-
anisms underlying regional fat expansion.Evidence arising from in vitro and in vivo studies suggests that the
differential regulation of fatty acid release and uptake in SAT and VAT
greatly affect their depot-speciﬁc metabolic properties (Table 4).
Overall, VAT adipocytes in men exhibit higher rates of fatty acid
turnover and lipolysis that in women, leading to a greater release of
free fatty acids into the circulation. Such differences provide a link be-
tween increased VAT and the metabolic risks associated with obesity.
Importantly, the long-term storage of fatty acids in the lower-body
(gluteal–femoral) depot, preferentially in women, provides a plausi-
ble explanation as to the protective properties of this depot from
ectopic fat accumulation and metabolic perturbations. Nevertheless,
the exact regulatory mechanisms of fatty acid metabolism remain to
be elucidated.
With the accumulating evidence for the beneﬁcial role of the femo-
ralWAT depot, it is important to characterize adipokine expression and
secretion in both upper- and lower-body WAT depots; as it is possible
that the gluteal–femoral depot could convey protection through a
beneﬁcial adipokine proﬁle. These analyses will facilitate categorizing
the importance and beneﬁcence of the known adipokines, but, impor-
tantly, include the continued discovery of novel adipokines. In addition,
accumulating data suggests that adipokines have paracrine effects on
preadipocyte cellular kinetics, as well as mature adipocyte metabolic
function or secretion, which demonstrates the multiple effects of
adipokines on metabolic health (Table 2).Acknowledgements
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